Logo

Notes for P&L

All amounts in SEKm unless otherwise stated

Note 6 Segment reporting

The division into business areas reflects AddLife’s internal organisation and reporting system. Operating segments are reported in a manner consistent with AddLife's internal reporting, which is submitted to the CEO, who has been identified as the highest executive within AddLife. AddLife reports business areas as an operating segment. AddLife reports its business areas as operating segments. The two business areas are Labtech and Medtech. This market grouping reflects a natural division of the Life Science market. AddLife uses EBITA (see definitions) as a performance measure when monitoring the business areas. Intra-Group sales are based on the same prices that an independent party would pay for the product.

Labtech

The companies in the Labtech business area operate within diagnostics and biomedical research, as well as laboratory analysis. The companies deliver directly to customers various products and solutions that include analytical instruments, equipment, microscopes, consumables and reagents, as well as software support and technical service, primarily to laboratories in medicine, research, academia and the food and pharmaceutical industries. The companies within the Labtech business area are mainly active in microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics and in the food industry. Customers are also offered training programmes in various areas to ensure that customers have the appropriate skills and to maximise user benefit from the products the Company provides.

Medtech

Medtech offers products and services in medical technology, as well as assistive devices for home care. The subsidiaries within the Medtech business area actively work with local presence and awareness among customers and suppliers. The companies provide products as well as services such as training, support, and maintenance. The product range spans from basic consumables to advanced instruments for surgical procedures, welfare technology, and assistive devices for the elderly and disabled. Overall, the product offering requires extensive medical expertise to guide customers correctly.

Data by operating segment
  2025   2024
  Labtech Medtech Group items and eliminations The Group   Labtech Medtech Group items and eliminations The Group
Net sales external 3,953 6,489 – 10,442   3,797 6,489 – 10,286
Net sales internal – 6 -6 0   – 7 -7 0
Net sales 3,953 6,495 -6 10,442   3,797 6,496 -7 10,286
Cost of goods sold -2,483 -3,988 6 -6,465   -2,427 -4,008 7 -6,428
Operating expenses -834 -1,302 -39 -2,175   -796 -1,500 -29 -2,325
Depreciation/amortisation of property, plant and equipment¹ -141 -241 -3 -385   -129 -242 -3 -374
EBITA 495 964 -42 1,417   445 746 -32 1,159
EBITA margin, % 12.5 14.8   13.6   11.7 11.5   11.3
Amortisation of intangible assets -84 -340 – -424   -78 -360 – -438
Operating profit 411 624 -42 993   379 398 -32 732
Financial items       -221         -316
Profit/loss before taxes       772         416
Income tax expense       -210         -151
Profit for the year       562         265
¹Depreciation of property, plant and equipment include depreciation/amortisation of right- of-use assets.
  2025   2024
  Labtech Medtech Group items and eliminations The Group   Labtech Medtech Group items and eliminations The Group
Assets¹ 2,393 9,465 853 12,711   2,586 10,028 441 13,055
Liabilities¹ 829 1,574 4,861 7,264   868 1,755 5,123 7,746
Investments                  
Property, plant and equipment² 112 267 0 379   138 334 0 472
Intangible non-current assets 28 92 0 120   80 23 0 103
Total 140 359 0 499   218 357 0 575
¹Does not include balances in Group accounts or financial transactions with Group companies.
²The amounts do not include the effects of corporate acquisitions.
Significant profit and loss items other than depreciation that do not correspond to payments
  2025   2024
  Labtech Medtech Group items The Group   Labtech Medtech Group items The Group
Capital gains -1 -4 – -5   -3 -3 – -6
Change in pension liability -4 1 3 0   -2 0 0 -2
Fair value change contingent consideration – – – –   – -7 10 3
Other items 6 -48 86 44   -13 5 -24 -32
Total 1 -51 89 39   -18 -5 -14 -37
  2025   2024
Data by country Net sales external Assets¹ Of which non-current assets   Net sales external Assets¹ Of which non-current assets
Sweden 1,226 1,421 901   1,097 1,435 929
Denmark 681 647 406   759 713 407
Finland 556 235 98   558 260 109
Norway 828 391 195   843 452 233
Ireland 1,330 3,306 2,925   1,274 3,648 3,215
Spain 1,078 1,386 815   985 1,569 894
United Kingdom 1,250 742 339   1,329 487 134
Germany 455 2,056 1,971   472 2,309 2,202
Italy 731 466 177   679 515 198
Switzerland 380 237 140   410 274 158
Other countries 1,927 1,300 557   1,880 1,246 597
Group items and unallocated assets – 524 38   – 147 50
Total 10,442 12,711 8,562   10,286 13,055 9,126
¹Does not include balances in Group accounts and financial assets. External net sales are based on the customers' location, and the carrying amounts of assets are based on where the assets are located.

The Group has no single customer whose revenue amounts to 10 percent of total revenue, and therefore no disclosures are provided in this regard.

  2025   2024
Investments in non-current assets Intangible Property, plant and equipment Total   Intangible Property, plant and equipment Total
Sweden 17 41 58   13 35 48
Denmark 18 12 30   2 38 39
Finland 0 14 14   1 6 7
Norway 3 13 16   7 19 26
Ireland 7 32 39   5 137 142
Spain 0 79 79   56 61 117
United Kingdom 63 56 119   0 70 70
Germany 2 7 9   3 5 8
Italy 2 36 38   2 44 46
Switzerland – 6 6   – 3 3
Other countries 8 83 91   13 55 69
Total 120 379 499   103 472 575
previous Note 5 Net sales by revenue type and business area
next Note 7 Employees and employee benefits expense

Loading...